The clinic results and safety of cholinesterase inhibiting drugs on Alzheimer disease
CHEN Tao
WANG Jinglei
SHI Jingjing
JIN Quanwei
LIU Yi
Abstract：Objective To investigate the clinical results and safety of cholinesterase inhibiting drugs on Alzheimer disease.Methods 72 cases of patients with Alzheimer disease were selected, which were treated in hospital from January 2015 to January 2016, and they were divided into the study group (36 cases) and control group (36 cases).The patients of control group were treated with quetiapine fumarate tablets ( an initial dose of 50 mg/d, bedtime;gradually increased to 100-400 mg/d) .On the basis of the control group, the patients of study group were treated with donepezil hydrochloride tablets ( an initial dose of 2.5-5 mg/d, orally at bedtime, increase to 10 mg /d after 1 week) .A course of two groups were all eight weeks.Compare the clinic results, adverse events, and changes of Mini Mental State Examination ( MMSE) , ADL Assess-ment Scale cognitive subscale ( ADAS cog) , activities of daily living scale ( ADL) and dementia pathology Behavior Scale (BEHAVE-AD), lipid peroxide (LPO ), superoxide dismutase (SOD) of two groups.Results The patients of the study group got a total efficiency of 94.4%, which was significantly better than the 77.8%of the control group (χ2 =4.181, P =0.041);The levels of MMSE score, SOD of the study group were significantly higher than those of the control group after the treatment ( t =5.269, t =1.753, t =4.797, t =4.380, t =2.459, t =1.723, P =0.000, P =0.041, P =0.000, P =0.000, P =0.000, P =0.044 );The levels of ADAS cog, ADL and BEHAVE-AD score, LPO of the study group were sig-nificantly less than those of the control group after the treatment ( t =4.797, t =4.380, t =2.459, t =1.723, P =0.000, P =0.000, P =0.000, P =0.044); There were drowsiness, nausea, paralysis, muscle tension, excitement, constipation and liver dysfunction and other symptoms occurred in patients of all two groups during treatment, but there was no significant difference between the two groups (χ2 =0.997,χ2 =0.997,χ2 =3.017,χ2 =2.060,χ2 =0.997,χ2 =0.504,χ2 =0.997, P =0.318, P =0.318, P =0.082, P =0.151, P =0.318, P =0.448, P =0.318 ).Conclusion With treating patients with Alzheimer disease, cholinesterase inhibiting drugs can obtain exact clinical efficacy, get fewer adverse reactions, and it is also safe, reliable, which makes it worthy of clinical application.
Keywords：Alzheimer diseaseCholinesterase inhibitorsEffectsSafety
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 809-812 )